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Title 
Prospective memory deficits in illicit polydrug users are associated with the average 
long term typical dose of ecstasy typically consumed in a single session. 
Abstract 
Rationale Neuroimaging evidence suggests that ecstasy-related reductions in SERT densities 
relate more closely to the number of tablets typically consumed per session rather than 
estimated total lifetime use. In order to better understand the basis of drug related deficits in 
prospective memory (PM) we explored the association between PM and average long-term 
typical dose and long-term frequency of use. Method Study 1: Sixty five ecstasy/polydrug 
users and 85 non-ecstasy users completed an event based, a short-term and a long-term time 
based PM task. Study 2: Study 1 data were merged with outcomes on the same PM measures 
from a previous study creating a combined sample of 103 ecstasy/polydrug users, 38 
cannabis-only users and 65 nonusers of illicit drugs. Results Study 1: Ecstasy/polydrug users 
had significant impairments on all PM outcomes compared to non-ecstasy users. Study 2: 
Ecstasy/polydrug users were impaired in event based PM compared to both other groups and 
in long-term time based PM compared to non illicit drug users. Both drug using groups did 
worse on the short-term time based PM task compared to nonusers. Higher long-term average 
typical dose of ecstasy was associated with poorer performance on the event and short-term 
time based PM tasks and accounted for unique variance in the two PM measures over and 
above the variance associated with cannabis and cocaine use. Conclusions The typical 
ecstasy dose consumed in a single session is an important predictor of PM impairments with 
higher doses reflecting increasing tolerance giving rise to greater PM impairment. 
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The aim of the present paper is to identify which aspects of long term 
ecstasy/polydrug use are associated with drug-related impairments of prospective memory 
(PM). PM is an aspect of real-world memory that involves remembering to carry out intended 
actions in the future (Einstein et al. 2005). PM tasks include both short-term and long-term 
activities that are triggered by external events (event-based) or the passage of time (time-
based). In short-term PM tasks, such as locking the car after leaving, there is a relatively short 
period of time between the external episode/prompt (leaving the car) and the appropriate 
behaviour (locking the doors). Long-term PM tasks, such as remembering to post a birthday 
card, have a longer time interval between the external episode/prompt (realization of a 
friend’s birthday) and the desired behaviour (posting a card). As to the cerebral mechanisms 
involved in PM processing, there is a general consensus that medial temporal hippocampal 
structures feature prominently (Adda, Castro, Além-Mar e Silva, de Manreza, & Kashiara, 
2008; Martins et al., 2007) as well as areas of the prefrontal cortex (PFC; Brooks, Rose, 
Potter, Jayawardena, & Morling, 2004; Burgess, Scott, & Frith, 2003; Katai, Maruyuma, 
Hashimoto, & Ikeda, 2003).  Considering that ecstasy users (Kish et al. 2010) and cannabis 
users (Jager et al. 2007) exhibit abnormalities in these brain regions, it is plausible to suggest 
that people using these drugs may demonstrate PM impairment. This proposal has received 
support with several studies using both self report and laboratory based measures 
demonstrating PM deficits in temporarily abstinent illicit substance users (e.g., 
Hadjiefthyvoulou, Fisk, Montgomery, & Bridges, 2011a; Heffernan, Jarvis, Rodgers, 
Scholey, & Ling, 2001a; Montgomery & Fisk, 2007; Rendell, Gray, Henry, & Tolan, 2007). 
Furthermore, former users of ecstasy have also exhibited event and time-based impairments 
in PM on the “Virtual Week” task (Rendell, Mazur, & Henry, 2009) highlighting the possible 
long-term neurotoxic potential of MDMA use.   
One key aspect that remains to be thoroughly explored is the presence of dose-related 
effects in relation to PM performance. It is important to demonstrate that these exist since in 
the absence of clear dose-related effects, any group differences that have been observed 
might more readily be attributed to some premorbid condition or lifestyle differences 
unrelated to drug use. However, in relation to ecstasy use and PM outcomes, there have been 
some problems with the way in which dose-related effects have been investigated. For 
example, in between group comparisons, using the self-report Prospective Memory 
Questionnaire (PMQ), while ecstasy/polydug related PM deficits have emerged in a number 
of studies, dose related effects have not been directly reported (Heffernan et al. 2001a; 
Heffernan, Ling, & Scholey, 2001b; Parrott et al. 2006). In other studies, lifetime use has 
been defined in a categorical manner in terms of the number of times that the drug has been 
previously used (e.g., 0, 1-9, 10-99, 100+ times). On this basis, lifetime use accounted for 
unique variance in long term PM problems on the PMQ, but not short term and internally 
cued PM problems (Rodgers et al. 2001). Montgomery and Fisk (2007) estimated lifetime use 
in terms of the number of tablets previously consumed but found no association between this 
variable and outcomes on the PMQ. Bedi and Redman (2008a) obtained estimates of lifetime 
ecstasy use (total number of tablets) from their participants as well as age of first use, and 
period of abstinence but none of these significantly predicted PMQ outcomes. 
Using objective measures of PM, Zakzanis, Young and Campbell (2003) found that 
ecstasy users differed from nonusers on the ‘appointment’ and ‘message’ PM subscales of the 
Rivermead Behavioural Memory Test (RBMT). Furthermore, the scores on the appointment 
subscale were significantly related to the number of occasions of ecstasy use and to the 
frequency of use (although the significant outcome was based on a sample size of fewer than 
20).  Bedi and Redman (2008b) included short term time and event based PM tasks in their 
test battery but ecstasy/polydrug group differences were either absent or inconclusive and 
dose related effects were not reported. Although Rendell et al. (2007) did not report effects in 
relation to lifetime dose, they found that frequent ecstasy users (using more than once a 
fortnight) performed worse than infrequent users (using less than one a month) who in turn 
performed worse than nonusers on all PM measures on the virtual week task. 
Hadjiefthyvoulou and co-workers found that lifetime ecstasy use (estimated number of 
tablets) was significantly associated with time and event based PM scores on the Cambridge 
Prospective Memory Test (CAMPROMPT) (Hadjiefthyvoulou et al. 2011a) and with 
performance on the RBMT and other short term time and event based PM tasks 
(Hadjiefthyvoulou et al. 2011b). However, these effects were no longer significant following 
controls for other drug use. It is also worthy of note that in these studies (Hadjiefthyvoulou  et 
al. 2011a; 2011b; Montgomery & Fisk, 2007) non users were included in the samples (with 
use coded as zero). Indeed this practice is common in much of the ecstasy-related behavioural 
research (e.g., Medina, Shear & Corcoran, 2005; Montgomery, Fisk, Newcombe, & Murphy,  
2005; Piechatzek et al. 2009; Reneman et al. 2001).  
 What this summary of the relevant literature demonstrates is that the issue of dose 
related effects in relation to laboratory measures of PM remains to be systematically 
investigated. For example, those studies quantifying use in a categorical manner may lose a 
degree of precision due to the ordinal nature of the scale and responses at the top end of the 
scale, e.g., 100+, do not reflect the actual differences among heavy users. Furthermore, when 
lifetime use is defined in terms of occasions of use, differences between individuals who 
might consume one tablet per occasion, versus others who might consume several tablets are 
masked. When dose-related effects are reported on the basis of distinctions between broadly 
defined groups, for example ‘heavy’ versus ‘moderate users’ or ‘frequent’ versus ‘infrequent 
users’ (e.g., Rendell et al. 2007), the group criteria are variable and even where the same 
criteria are used widely different cut off points may be adopted. Clearly, comparisons 
between user groups defined in this manner might be useful but they are less informative than 
correlational indicators and make informed comparisons between studies difficult, if not 
impossible. Including non users of specific drugs in the sample (with their use coded as zero) 
when dose-related effects are evaluated is also potentially problematic since a significant 
correlation or regression coefficient may be due to the absence of use within the drug naïve 
participants (i.e., the group effect) rather than a trend within the drug using participants. 
Indeed when the correlation is limited to the drug users within the sample it may no longer be 
significant.  
Lastly, it is also possible that that estimates of lifetime use which do not suffer from 
the limitations identified above may still fail to capture subtle differences in the patterns of 
use between ecstasy users. Consistent with this possibility, Morefield, Keane, Felgate, White, 
and Irvine (2011) found that there were pronounced differences in the consumption patterns 
of their sample in terms of the number of tablets consumed in a single session. Furthermore 
they found that a non linear relationship existed between the number of tablets consumed in a 
single session and MDMA plasma concentrations with the latter increasing exponentially 
with the number of tablets consumed. Thus for those consuming no more than a single tablet, 
MDMA plasma concentrations peaked and remained stable after an hour or so, while those 
consuming more than a single tablet experienced a dose related disproportionate rise in 
plasma levels which continued to increase through out the five hour period during which 
levels were monitored. Therefore, taking a single tablet often or multiple tablets infrequently 
may give rise to similar lifetime doses but have very different consequences in terms of the 
typical level and peak duration of blood plasma MDMA levels. 
 A potential implication of this is that more emphasis should be placed on the size of 
the typical dose rather than other measures such as frequency of use and lifetime dose. The 
importance of alternative measures has also emerged from neuroimaging studies. For 
example, Thomasius et al. (2003) found that distribution volume ratios (DVRs) of SERT 
ligands in some sub-cortical structures  were best predicted by the usual dose of ecstasy 
consumed at a typical party event, while in other instances  DVRs were best predicted by the 
amount of ecstasy consumed in the 12 months prior to testing. Estimates of lifetime use and 
maximum dose of ecstasy were either non significant or accounted for significantly less 
unique variance. 
The present study aimed to further investigate dose related effects on PM performance 
by using a timeline technique similar to that adopted by Medina et al. (2005) and Bedi and 
Redman (2008b) in order to examine long term dose related effects . For each illicit drug, we 
will obtain an estimate of the typical dose and frequency of use for each year since use 
commenced. These two variables have received relatively little attention previously. 
Furthermore they can be used to produce an estimate of lifetime use. In the analysis of dose 
related relationships presented here only users of specific drugs will be included. Non users 
will be excluded from these particular analyses and we will seek to maximise the size of the 
available sample by combining samples from different phases of data collection. In Study 1, a 
replication and extension of previous findings are presented. In Study 2, data from Study 1 
will be augmented with equivalent data which, although collected in a previous study, has yet 
to be analysed. The resulting combined data set will allow us to more effectively investigate 
polydrug dose related effects. Specifically Study 2 will focus on the effects of the long term 
average number of tablets consumed in a single session and the long term average frequency 
of use. 
 
STUDY 1 
METHOD 
Participants. 
Participants included 65 ecstasy/polydrug users (27 females, 37 males, 1 not 
reported), and 85 non-ecstasy users (54 females) (for demographic details see Table 1). 
Females predominated among the non-ecstasy user group and males among the 
ecstasy/polydrug users, producing a significant gender effect, χ2 (1) =6.70, p<.01. 
Participants, who were university students studying in the United Kingdom, were recruited 
via direct approach. Fifty-seven of the participants included here took part in a previous study 
from our laboratory. However, their results on the laboratory PM tasks have not been 
previously reported and are presented here for the first time. None of the present sample 
reported use of ecstasy within the week prior to testing and none reported using any other 
illicit drug within the 24 hours prior to testing. All participants gave verbal consent and were 
tested in accordance with the national and local ethics guidelines and the Declaration of 
Helsinki. 
Materials 
The use of ecstasy and other drugs was assessed by means of a self-report 
questionnaire previously used in several studies from our laboratory. For all illicit drugs that 
were regularly consumed and for each year since they commenced drug use, participants 
estimated the typical dose that they ingested in a representative session and their typical 
frequency of use (number of sessions per week) during that year. These annual estimates 
were used to produce an estimate of total lifetime use. Participants also indicated their current 
frequency of use and the period of abstinence for each major illicit drug. Demographic 
variables including age, gender, and years of full time education were recorded and fluid 
intelligence was measured through Raven’s progressive matrices (Raven, Raven & Court, 
1998).  The current use of cigarettes and alcohol were also recorded.  
Laboratory Measures of Prospective Memory. 
Pattern Recognition PM Task: This test utilises a processing speed task which was 
amended to include a parallel PM element. The task involved classifying pairs of patterns 
which increased in complexity as either the same or different while remembering to press the 
F1 key each time that the complexity level increased (purportedly to save the participant’s 
scores). The task was repeated three times. The number of times the participant forgot to 
press F1 for each trial was calculated producing a laboratory event-based PM measure. 
Fatigue Short-Term Time-Based PM Test: Following the briefing, participants were 
told that they should provide an indication of their level of fatigue (using the Karolinska 
Sleepiness Scale: Gillberg, Kecklund, & Akerstedt, 1994) every 20 minutes throughout the 
experiment or if this occurred during the completion of a task, to do so immediately after. 
The percentage of occasions on which this was done was calculated separately for the first 
and second half of the test session thereby producing two measures of short-term time-based 
PM. On each occasion, participants who forgot were reminded to fill in the questionnaire. 
Mail Long-Term Time Based PM Test: During the test session participants learned a 
list of 15 words over five trails. A long-term PM element was added in which participants 
had to remember to return an answer sheet, in a prepaid envelope, to the experimenter with 
the words that they were able to recall after a delay of one, two, and three weeks from the 
time of testing. Participants scored 1 if the envelope was returned and 0 otherwise yielding a 
maximum possible score of three. 
Full descriptions of the tasks may be found in Hadjiefthyvoulou et al. (2011b).  
 
Procedure 
The tests were administered under laboratory conditions. The Ravens intelligence test 
was administered first followed by the age/education questionnaire. Next the F1 event based 
task was administered and instructions for the long-term time based task were provided.  The 
fatigue short-term PM task was administered throughout the session and the drug use 
questionnaire was administered at the end. Participants were fully debriefed, given a 20 GBP 
supermarket (grocery store) gift card and given drug education leaflets. Participants also 
performed a range of other tasks that are beyond the scope of the present investigation. 
 
Design and Statistics. 
A between-participant design was used with drug user group (ecstasy/polydrug versus 
non-ecstasy user) as the independent variable. Dependent variables included all of the PM 
measures, i.e., the proportion of fatigue questionnaires completed during the first and second 
half of the test session, the number of times that participants forgot to press the F1 key for 
each of the three trials and the number of delayed recall tests participants remembered to mail 
back to the experimenter. Group differences were analysed via t test. 
 
RESULTS AND DISCUSSION 
Regarding background variables, inspection of Table 1 reveals that the two groups 
differed significantly in terms of age and the number of cigarettes consumed each day. 
Ecstasy/polydrug users were older and consumed more cigarettes. Furthermore, the 
ecstasy/polydrug group had a significantly higher level of lifetime cannabis use and a 
significantly shorter period of abstinence from the drug. Although ecstasy/polydrug users 
reported a higher current frequency of cannabis use, the difference was short of statistical 
significance. Ecstasy/polydrug users were significantly impaired on all but two of the PM 
measures and on these remaining two, the difference approached statistical significance (see 
Table 1). 
The present results replicate the findings from our previous study. Ecstasy/polydrug 
users made significantly more errors (forgetting to press F1) on each of the three trials of the 
event based task; they completed significantly fewer Karolinska fatigue questionnaires during 
both halves of the test session, with the deficit larger in magnitude during the second phase of 
testing; they also returned fewer delayed recall tests during the three weeks following the test 
session. 
 
STUDY 2 
Of the non-ecstasy users included in Study 1, over one third had used cannabis and 
10% cocaine and the majority of these individuals appeared to be current users. Similar 
proportions were using these drugs among non-ecstasy users in our previous study. Since 
there is evidence to suggest that cannabis use is associated with self report (Fisk & 
Montgomery, 2008; Rogers et al. 2001) and laboratory based (McHale & Hunt, 2008; 
Montgomery, Seddon, Fisk, Murphy, & Jansari, 2012) PM deficits, the group difference 
evident in Study 1 and in our previous paper may actually underestimate the true difference 
between ecstasy/polydrug users and drug naïve individuals. Inclusion of a cannabis only user 
group and a group of nonusers of illicit drugs would clarify the nature of the ecstasy/polydrug 
related deficit and also allow us to directly test for group differences between cannabis-only 
users and nonusers of illicit drugs.  
Most importantly, as outlined above, it has often not been possible to demonstrate 
clear long-term dose related effects of ecstasy and other illicit drugs on aspects of prospective 
memory. Rather than relying on single estimates of lifetime use, it may be useful to focus on 
other long-term aspects of use including the long-term dose (e.g., tablets, lines or joints 
typically consumed per session) or the long-term frequency of use.  Merging the sample from 
Study 1 with that of our previous study will create a sufficiently large sample in order to 
explore the associations between these long-term measures of illicit drug use and the PM 
outcomes. A larger sample size will help establish whether measures such as long-term 
average dose per session and frequency of use can explain variance in PM performance 
where more traditionally used measures of drug use such as total lifetime use, current 
frequency of use, period of abstinence, duration of use and average weekly long-term 
consumption may fail to reveal such a relationship. 
 
METHOD 
Participants. 
One hundred and three ecstasy/polydrug users (51 females, 51 males, 1 not reported), 
38 cannabis-only users (21 females), and 65 nonusers of illicit drugs (48 females) took part in 
this investigation (for demographic details see Table 2). The gender composition differed 
significantly between the groups with females predominating among the non illicit user group 
and a broadly even split among the cannabis only and ecstasy/polydrug users, χ2 (2) = 9.51, 
p<.01. Participants, who were university students studying in the United Kingdom, were 
recruited via direct approach.  
In addition to the individuals included in Study 1, 69 of the participants included in 
the present study also took part in our earlier study where we have previously reported some 
of the laboratory PM results for these individuals. Merging the samples together allowed us 
to include a cannabis only user group and a group of non-users of illicit drugs (in Study 1 the 
non-ecstasy user group contained a substantial minority of cannabis users and a small number 
of cocaine users). It also enabled us to create sufficient numbers of illicit drug users so that 
long and short-term dose-related effects could be properly investigated. None of the present 
merged sample reported use of ecstasy within the week prior to testing and none reported 
using any other illicit drug within the 24 hours prior to testing. All participants gave verbal 
consent and were tested in accordance with the national and local ethics guidelines and 
according to the Declaration of Helsinki. 
 Materials 
The drug use and demographics questionnaires (and measures) were the same as those 
that featured in Study 1. In addition, in the present study, the historical annual estimates of 
typical dose per session and frequency of use for each year were considered separately and 
estimates of long-term dose (averaged over the number of years of use) and similarly the 
long-term average frequency of use were computed. This was done for each illicit drug that 
was regularly consumed.   
 
Laboratory Measures of Prospective Memory 
The same PM tasks were administered as in Study 1, that is, the F1 Short-Term Event 
Based Task, the Fatigue Short-Term Time Based Test, and the Mail Long-Term Time Based 
Test. Full descriptions of these may be found above. 
 
Procedure 
The procedure was the same as that outlined in Study 1. 
 
Design/Statistics 
A mixed design was used to analyse outcomes from the fatigue short-term time based 
PM task. The proportion of fatigue questionnaires completed in the first half and second 
halves of the test session were compared across the three participant groups 
(ecstasy/polydrug, cannabis only, and non-illicit drug user). To explore any differences on the 
F1 event based PM task (omitting to press F1) a mixed design was again used.  The number 
of errors was compared across three separate trials and between the three participant groups 
(ecstasy/polydrug, cannabis only, and non-illicit drug user).   Responses from the mail long-
term time based PM task were compared between the three user groups (ecstasy/polydrug, 
cannabis only, and non-illicit drug user) using a one way design. In all three analyses, gender 
and measures of current alcohol and cigarette use were included as covariates. With respect 
to the between participant comparisons, it was predicted, a priori, that non users would score 
significantly better than both cannabis only and ecstasy/polydrug users. For these two 
pairwise comparisons, an alpha value of .025, one-tailed, was selected. No prediction was 
made regarding the difference between the two drug using groups.  
For those individuals using illicit drugs, associations between indicators of long and 
short-term drug use and the outcomes on the PM measures were investigated using 
correlation. It was predicted that increasing levels of illicit drug use would be associated with 
poorer PM performance and that PM performance would be positively associated with the 
period of abstinence.  
While some means of controlling the Type 1 error rate is required it is now well 
established that full Bonferroni correction greatly inflates the likelihood of Type 2 error 
(Rothman, 1990). Where test results are conditionally dependent, (as is the case with the 
present study, where there are multiple interrelated outcome variables and multiple inter-
correlated drug use measures) full Bonferroni correction is known to be inappropriate (Bland 
& Altman, 1995; Narum, 2006; Pike, 2010). Thus an alternative to full Bonferroni correction 
has been adopted here, which focusses on controlling the False Discovery Rate (FDR), a 
technique which is well suited to situations where the reported outcomes are not independent 
(Benjamini & Yekutieli, 2001). This involves controlling the proportion of occasions where 
true null hypotheses are falsely rejected giving rise to ‘false discoveries’. Computational 
methods are available for calculating the critical value for alpha (also known as the q value) 
which controls the FDR at a given level (e.g., Pike, 2010). The FDR rate in the present study 
was set to .10 which implies that the proportion of significant outcomes which are actually 
false discoveries is limited no more than 10%. In fact, in the present case, significant 
outcomes that were not in the predicted direction are also rejected which effectively reduces 
the FDR to .05. There is a related procedure for calculating the critical alpha value which 
limits the Family Wise Error rate (FWE) to .05 without greatly inflating the risk of a Type 2 
error, as is the case with full Bonferroni correction (Benjamini & Yekutieli, 2001; Narum, 
2006). It is this critical level and the related FDR which has been used to identify those 
outcomes in Tables 4 and 5 which can be regarded as statistically significant with the FWE 
<.05 and FDR<.10, two tailed. 
  
 
RESULTS 
Group differences on the background variables are set out in Table 2. 
Ecstasy/polydrug users were significantly older than nonusers. Both illicit drug using groups 
consumed significantly more units of alcohol per week than nonusers. Ecstasy/polydrug users 
smoked significantly more cigarettes each day compared with cannabis only and nonusers. In 
terms of illicit drug use, aside from ecstasy, most ecstasy/polydrug users regularly consumed 
cannabis and two-thirds of the group were regular cocaine users (see Table 3). On virtually 
all of the cannabis use measures set out in Table 3 ecstasy/polydrug users registered 
significantly greater cannabis use compared to cannabis only users. 
 
The F1 event based PM task.  
Examination of Table 2 reveals that relative to the other two groups, ecstasy/polydrug users 
committed more errors on this task by failing to press F1 at the end of each 30 second period 
on each of the three trials. Cannabis only users and non-illicit drug users performed similarly 
on this task. ANCOVA was administered with gender, daily cigarette and weekly alcohol 
consumption as covariates. Mauchly’s test of sphericity was statistically significant, p<.001, 
therefore Greenhouse-Geisser adjusted degrees of freedom have been used. The interaction 
between drug user group and trial was non significant, F<1. There was a significant effect of 
trial, F(1.45,268.40)=7.97, p=.002, ηp2 = .041, and the groups differed significantly, F(2,185) 
= 7.28, p=.001, ηp2 = .073. Pairwise comparisons revealed that ecstasy/polydrug users 
committed significantly more errors than drug naïve persons, and cannabis only users, p<.001 
and p=.008 respectively. Drug naïve persons and cannabis only users did not differ 
significantly, p>.05. None of the covariates were statistically significant, p>.19, and 
homogeneity of regression was obtained in all three cases. 
 
The fatigue short-term time based PM task. Inspection of Table 2 reveals that non 
illicit drug users did best, remembering to complete more fatigue questionnaires than the 
other two groups. Cannabis-only users performed worse than non illicit drug users but better 
than ecstasy users. ANCOVA with the same covariates included as in the previous analysis 
revealed a significant interaction between drug user group and test session, F(2,184)=7.42, 
p=.001, ηp2 = .075. As is clear in Table 2, while both user groups performed worse than 
nonusers during the first half of the session, nonusers broadly maintained their performance 
in the second half while the performance of the drug using groups deteriorated further. For 
the sample as a whole, performance deteriorated between the first and second halves of the 
session, F(1,184)=35.25, p<.001, ηp2 = .161. The overall group difference was significant, 
F(2,184)=25.43, p<.001, ηp2 = .217. Pairwise comparisons revealed that, overall, both user 
groups performed significantly worse than nonusers, p<.001 in both cases. Furthermore, the 
ecstasy/polydrug group performed significantly worse than cannabis only users, p=.020, one 
tailed. None of the covariates were statistically significant, p>.20, for alcohol and nicotine 
consumption, although gender approached significance as a covariate, F(1,184)=3.84, 
p=.052, ηp2 = .020. Homogeneity of regression was obtained in all three cases. 
The mail long-term time based PM task. As is clear from inspection of Table 2, 
non-illicit drug users remembered to return more delayed recall tests compared to the other 
two groups. Ecstasy/polydrug users again performed worse on this measure, with cannabis 
only users scoring in between. ANCOVA with the same three covariates failed to yield a 
statistically significant group difference, F(2,185)= 2.06, p=.131, ηp2 = .022.  However 
pairwise comparisons revealed that non illicit drug users scored significantly higher than 
ecstasy/polydrug users, p=.023 one-tailed. None of the other pairwise comparisons were 
statistically significant, p>.05. None of the covariates were statistically significant, p>.45, for 
gender and nicotine consumption, although alcohol consumption approached significance as 
a covariate, F(1,185)=3.39, p=.067, ηp2 = .018. Homogeneity of regression was obtained in 
all three cases. 
Associations between long-term drug use and PM. A key objective of the present 
paper was to examine the association between the various laboratory PM measures and the 
long-term average dose per session and long-term average frequency of use for ecstasy, 
cocaine and cannabis. The corresponding correlations are presented in Table 4. Inspection of 
Table 4 reveals that, without adjustment for multiple comparisons, the long-term average 
dose of ecstasy is significantly associated with all but one of the PM measures. Using 
Benjamini and Yekutieli’s (2001) procedure for controlling the FWE, four of the eight 
correlations are statistically significant at FWE < .05, and using a two tailed FDR<.10 with 
m=48, five of the correlations are significant. It is also apparent that prior to adjustment for 
multiple comparisons, the long-term average frequency of cannabis use was significantly 
associated with the two time based PM measures, however, only the association with the 
Fatigue short term measure remains significant after controlling the FWE and FDR at the 
levels indicated above.  
Examination of the more traditional measures of illicit drug use set out in Table 5 
shows that, prior to adjustment for multiple comparisons, a number of these were 
significantly associated with individual PM outcomes. The fatigue short term measure 
(during the first half of the test session) was significantly associated with five of the drug use 
variables, four relating to aspects of ecstasy use and one to cocaine.  Similarly, F1 event 
based PM task performance in Trial 1 was significantly associated with five of the drug use 
variables, two relating to aspects of ecstasy use and three to cocaine. These account for most 
of the unadjusted significant outcomes in Table 5.  However, it is important to note that 
following control of the FWE rate at less than .05 only two of these associations remained 
statistically significant. Furthermore controlling the FDR at 0.10, two tailed, left none of the 
associations statistically significant. Clearly both these methods for controlling Type 1 error 
are sensitive to the number of comparisons made (i.e., m=120 in Table 5). It might be argued 
that the number of comparisons should be treated separately for each aspect of drug use. 
FWE and FDR analyses were repeated on each separate block of 24 comparisons (i.e., m=24) 
and as with the full analysis in each case none of the outcomes achieved significance at a 
level which guaranteed FDR<.10. Similarly, for each separate block of 24 comparisons, only 
the same two correlations were such that FWE <.05, i.e., the association between total 
cocaine use and F1 event based PM performance in Trial 1 and between the average weekly 
consumption of ecstasy and performance during the first half of the Fatigue short term time 
based PM task.  
For the seven statistically significant associations listed in Table 4 with the two tailed 
FDR<.10, partial correlations were conducted controlling for the long term average dose and 
frequency of use of the other main illicit drugs. Thus, the association between the relevant 
PM measures and the long term average dose of ecstasy was estimated while controlling for 
long term average frequency of ecstasy, cannabis and cocaine use and long term average dose 
of cannabis and cocaine. Similarly the association between the relevant PM measures and the 
long term average frequency of cannabis use was estimated while controlling for the long 
term average frequency of ecstasy and cocaine use and long term average dose of ecstasy, 
cannabis and cocaine. The resulting partial correlations (df=53) between the long term 
average dose of ecstasy and respectively the fatigue time based total, and first half 
performances were -.267 and -.279, and between the long term average dose of ecstasy and 
respectively the F1 event based total, and Trial 3 outcomes were .269 and .290. These four 
remained significant with FDR<.10 (m=7, two tailed). However the remaining partial 
correlations between the long term average dose of ecstasy and  F1 event based Trial 1 
performance, i.e., .164, and between the long term average frequency of cannabis use and the 
fatigue time based total, and first half performance, respectively -.163, and -.169, were not 
significant at a level which controlled the FDR at less than .10.  Furthermore, while these 
outcomes are informative none of the associations met the threshold for controlling the FWE 
at less than .05 two tailed (although on a one tailed basis one of the significant FDR outcomes 
met the FWE criterion, p=.016, and all of the remainder approached significance, .02 ≤ p ≤ 
.025, one tailed, compared with the critical value of .019).   
 
General Discussion 
The present findings are consistent with previous studies (Hadiefthyvoulou et al. 
2011a; Heffernan et al. 2001a; Montgomery & Fisk, 2007; Rendell et al. 2007) and support 
the view that ecstasy/polydrug use is associated with deficits in short term time and event 
based PM and in long term time based PM. However, we demonstrate here that outcomes on 
both the event and time-based short term PM measures are significantly associated with long 
term differences in the average dose of ecstasy consumed in a single session. Furthermore, 
the inclusion of a cannabis-only group showed that while ecstasy/polydrug users performed 
significantly worse than non illicit drug users on the FI event based task, cannabis-only users 
did not, which therefore suggests that the deficit here is due to some characteristic of 
polydrug use unrelated to cannabis consumption.  
Interestingly cannabis-only uses were impaired in short term time based PM relative 
to drug naïve persons suggesting a direct effect of cannabis on this aspect of PM functioning. 
Indeed, both user groups exhibited significant deficits relative to drug naïve persons on the 
Fatigue PM measure during the second half of the test session. Furthermore ecstasy/polydrug 
users were significantly impaired relative to cannabis-only users on this measure.  It is also of 
interest to note that the long term average frequency of cannabis use (among illicit drug 
users as a whole) was significantly associated with performance on the Fatigue PM measure 
(although interestingly this was during the first half of the test session).  
Almost 90% of ecstasy/polydrug users in the present study also used cannabis and 
approaching 80% used cocaine, thereby raising the possibility that the effects on PM 
performance that we observed may be due to any one of these three major drugs, or to 
cocktail effects associated with their joint consumption. The evidence set out in Tables 4 and 
5 appears to suggest that it is the long term average dose of ecstasy which is linked to most of 
the PM deficits that have been observed in the present paper. This appears to share 
statistically significant variance with most of the PM measures. Furthermore, when we 
controlled for the effects of cocaine and cannabis, the negative associations between the long 
term typical average dose of ecstasy (per session) and performance on two of the three PM 
measures remained statistically significant, at least at a two tailed FDR <.10.  
A key aspect of the present results is the importance of the long term typical dose of 
ecstasy in a single session. This appears to be directly related to adverse outcomes on the PM 
measures. This finding may be a corollary of the development of tolerance. Indeed, it has 
been demonstrated that the subjective effects of taking ecstasy diminish quite rapidly, leading 
many users to progressively increase their dose so as to maintain the intensity of the 
experience. In an extensive review of the literature Parrott (2005) attributes tolerance to 
serotonergic neurotoxicity. Consistent with this proposition, animal studies in rodents and 
primates have demonstrated long term reductions in serotonin, its metabolite 5-HIAA and in 
serotonin axon densities (e.g., Commins et al. 1987; Hatzidimitriou, McCann & Ricuarte, 
1999) and neuroimaging studies in regular ecstasy users have demonstrated reduced SERT 
densities across the neocortex, and clear evidence of serotonin axonal damage and grey 
matter loss (Cowan et al. 2003; Kish et al. 2010). The progressive degeneration of the 
serotonergic system means that there are fewer sites for the drug to operate on thereby 
requiring increasing amounts to achieve the same pharmacological reaction (Parrott, 2005). 
The development of tolerance would lead to progressively larger doses and many users may 
resort to periodic binging (i.e., ‘stacking’ or ‘boosting’) to maintain the intensity of the 
subjective experience. 
If drug use continues unabated, long term, then the increasing individual doses 
associated with growing tolerance will necessarily give rise to increased lifetime exposure 
and thus long term average dose and lifetime use will be co-related. However, the 
relationship is not necessarily isomorphic. For example, in Verheyden, Henry and Curran’s 
(2003) sample, a significant number had cut back their use of the drug for various reasons 
(e.g., financial, adverse physical effects, adverse effects on work or education or because of 
the reduced subjective effects). Furthermore, in Scholey et al’s (2004) sample while 24% of 
heavy users (more than 100 occasions of use) reported normal doses of between 3-4 tablets 
and 14% doses of 4+ tablets, the majority were normally consuming between 1-2 tablets per 
session, the same as the majority of moderate and novice users. Thus long term trends in the 
typical dose per session may not always show a straight forward relationship with total 
lifetime use. 
The exact mechanisms through which MDMA causes neurotoxicity remain unclear. 
Recent investigations have suggested a role for cortisol in the process. Parrott (2009) notes 
that, in laboratory studies, administration of MDMA stimulates the hypothalamo-pituitary-
adrenal (HPA) axis resulting in increased plasma concentrations of cortisol. In a study 
examining salivary cortisol levels in ecstasy users, increases of up to 800% were observed in 
participants who were clubbing and on drug compared with baseline and compared with 
dancing while drug free (Parrott, Lock, Conner, Kissling & Thome, 2008). In another recent 
study, Wolff et al. (2012) evaluated cortisol levels pre and post clubbing. Interestingly, at 
baseline, cortisol levels were elevated in their sample compared with normal population and 
diurnal norms. Post clubbing, increases in cortisol levels were again more pronounced in 
clubbers who had consumed ecstasy relative to those who had not. Furthermore, genetically 
based differences in the efficiency of drug metabolism moderated this effect. Specifically, 
post clubbing increases in cortisol among the ecstasy users were largely limited to those with 
the two CYP2D6 phenotypes characterised by poor or intermediate metabolism. A second 
genetic influence was apparent, linked to the COMT genotype (Met/Met) that is associated 
with low activity drug metabolism. Those associated with this particular phenotype registered 
larger increases in cortisol post clubbing irrespective of whether they had taken MDMA. 
Wolff et al (2012) observe that regular use of MDMA may lead to chronic HPA axis 
dysregulation particularly in those with a genetic makeup characterised by poor xenobiotic 
metabolism. 
In turn, it is possible that MDMA induced, cortisol mediated, HPA axis dysregulation 
may be responsible for some of the cognitive deficits associated with ecstasy use. Cortisol is 
known to directly affect learning and memory as well as attentional processes in an inverted 
U shaped manner with too much or too little resulting in cognitive impairment. It is directly 
involved in regulating the activity of a number of neurotransmitters that are crucial in 
supporting prefrontal executive processes including dopamine. Furthermore, chronically 
elevated levels have been associated with atrophy in the striatum, hippocampus and 
prefrontal cortex (Erickson, Drevets & Schulkin,  2003). 
Whether ecstasy’s neurotoxic effects are directly associated with MDMA, its 
metabolites, or produced indirectly via the effects on cortisol, it is of interest to consider 
which of the neural areas associated with PM performance may be susceptible to the drug. 
Over the previous several years much has been learned as to the neural basis of PM 
performance. In early neuroimaging research it was demonstrated that increased activity in 
the lateral frontopolar region, Brodmann area (BA) 10, was associated with retaining the PM 
intention, while, when the cue was detected, activity in medial BA 10 appeared to decline as 
attention was diverted away from the external ongoing task and the focus was switched to the 
internal representation of the PM intention (Burgess, Quayle & Frith, 2001; Burgess et al. 
2003). Later research has demonstrated the involvement of other cortical and subcortical 
areas. During the storage phase, in addition to lateral BA10, activity is also higher in the 
bilateral medial frontal gyrus (BA 8/32), the left precuneus and left parietal cortex (BA7) 
(Benoit, Gilbert, Frith, & Burgess, 2012), as well as a region in BA46 extending to the insular 
cortex and the anterior cingulate (Gilbert, 2011). Responding to the cue and retrieving the 
intention also results in increased activity in the VLPFC and lateral parietal cortex, the 
anterior cingulate, more superior regions of the DLPFC, as well as the orbitofrontal cortex 
(OFC) (Simons, Schölvinck, Gilbert, Frith & Burgess,  2006). Findings reported by Gilbert 
(2011) suggest that the specific content of the PM intention and the characteristics of the PM 
cue are not actually stored in BA10 but rather are reflected in differential activation 
elsewhere in both cortical (e.g., the medial rostral prefrontal and right superior parietal 
cortices, the medial occipital cortex) and subcortical structures (e.g., thalamus, putamen). 
It is known that ecstasy damages axonal tissue though out much of the neocortex and 
it may be that one or more of the above mentioned neural areas may be particularly sensitive 
to ecstasy-related effects. The acute effects of ecstasy on PM were investigated in Ramaekers 
Kuypers, Wingen, Heinecke and Formisano’s (2009) study in which participants, who were 
regular ecstasy users, performed an event based PM task. While performing the ongoing task 
and retaining the PM intention, fMRI revealed that relative to placebo, the BOLD response 
was reduced following the administration of MDMA in the left thalamus, left putamen, left 
precuneus (BA7), the left inferior /superior parietal lobule (BA40/7) and right inferior 
parietal lobule (BA40). When retrieving the PM intention administration of MDMA reduced 
the BOLD response in the inferior parietal lobe (bilateral BA40). Clearly many of the regions 
demonstrating acute MDMA sensitivity are the same as those supporting event based PM 
processing, e.g., the parietal cortex, the thalamus and putamen, and it may be that the same 
regions are implicated with respect to PM deficits in currently abstinent ecstasy/polydrug 
users. 
Since the ecstasy/polydrug users in the present study were also impaired in time based 
PM, it is of interest to consider which neural areas might be implicated in this regard. Okuda 
et al. (2007) demonstrated that the lateral frontopolar cortex is also active in storing the 
intention in time based PM, although there were slight differences, with the left superior 
frontal gyrus (BA9/10) more active in time based PM. Relative to event based PM, using a 
clock, instead of subjective time estimation, was associated with greater activation in the 
right superior frontal gyrus (BA10), the medial frontal lobe (BA10) and the adjoining anterior 
cingulate gyrus (BA32/10). In a later study, Momennejad and Haynes (2012) focussed on the 
specific content of the PM intention showing that, during retention, this was encoded in a 
range of medial PFC regions including BA 9/ 10, as well as left lateral BA 6, and the 
occipital lobe (BA17, right inferior BA19) . Differences in the specific timing of the PM 
intention appeared to be encoded in the lateral PFC including bilateral BA10, right BA46, 
and BA6, as well as right medial BA10, right posterior parietal lobe, right superior parietal 
cortex, and the anterior cingulate. At the point of retrieval different delays were associated 
with differential activation in additional regions including the right precuneus, the inferior 
right PFC (BA45) and orbitofrontal cortex (BA47). 
The neuroimaging results have been augmented by clinical and lesion studies. For 
example, in a study of patients with focal brain lesions, following appropriate controls, right 
polar prefrontal (BA10) lesions were associated with a deficit in time-based PM while event-
based PM performance was unrelated to lesion status. Interestingly, patients with frontopolar 
lesions were also significantly impaired in time estimation ability compared to other patients 
(Volle, Gonen-Yaacovi, de Lacy Costello, Gilbert, & Burgess, 2011). In another study, the 
relationship between PM performance and grey matter volumes in the medial temporal, 
prefrontal and parietal regions was examined in a sample of normal and mildly demented 
older adults. A significant positive association was apparent between medial temporal and 
more specifically hippocampal grey matter and performance on a focal PM task (Gordon, 
Shelton, Bugg, McDaniel, & Head, 2011).  Lastly, Kondo et al. (2010) administered diffusion 
tensor imaging (DTI) on subjects with diffuse axonal injury, revealing a significant 
association emerged between PM performance and the degree of fractional anisotropy (an 
indication of axonal damage) , in the left parahippocampal gyrus, left inferior parietal lobe, 
and left anterior cingulate. 
Given the range of neural areas which appear to support time based PM processes, it 
is of interest to consider which of these may feature in the ecstasy-related deficits that have 
been observed here. Cowan et al. (2003) assessed regional brain grey and white matter 
concentration in ecstasy users and controls. The former had decreased grey matter in several 
brain regions, which were localised to the neocortex in bilateral occipital cortex (BA 18), left 
middle temporal gyrus (BA 21) and left inferior frontal gyrus (BA 45). Kish et al. (2010) 
investigated differences between ecstasy users and controls in serotonin transporter densities, 
the regional volume of grey and white matter and cortical thickness in particular ROIs. 
Consistent with the outcomes of previous studies (e.g., Buchert et al. 2004; Thomasius et al. 
2006) the results revealed that SERT densities were significantly reduced in all cortical areas 
with the occipital and temporal cortices most affected. No significant differences in SERT 
binding emerged in the basal ganglia structures or the thalamus. Cortical thinning was evident 
especially in left hemisphere locations including the superior (BA6) middle  (BA10 and BA9) 
and inferior (BA47) frontal gyri, inferior parietal (BA40), middle temporal gyrus (BA22), 
occipital cortex (BA17) and right inferior parietal. Furthermore the neural deficits evident in 
ecstasy/polydrug users were associated with aspects of prior ecstasy consumption (Kish et al. 
2010). 
Combining, the evidence set out above concerning the neural basis of PM 
performance and what is known regarding neural damage in ecstasy users, one clear area that 
is implicated is the frontopolar cortex (lateral BA10) which plays a crucial role in both time 
and event based PM (e.g., Gilbert, 2011; Okuda et al. 2007) and which has been to shown to 
exhibit reduced SERT densities and cortical thinning in ecstasy/polydrug users (e.g., Kish et 
al, 2010). Indeed as noted above patients with right polar prefrontal BA10 lesions were 
shown to be impaired in time based PM (Volle et al. 2011). It is also possible that the DLPFC 
more generally (including BA6 BA9) may similarly be implicated. Also the parietal cortex 
cannot be excluded since it has been identified as playing a role in time and event based PM 
and also exhibited reduced SERT densities and cortical thinning in Kish et al’s (2010) study. 
Furthermore, reduced activity in areas of the parietal cortex, following acute MDMA 
administration, was shown to be directly associated with impaired PM performance 
(Ramaekers et al. 2009). 
A number of limitations need to be acknowledged in relation to the present study. In 
common with much of the existing literature, this study has relied on self-report data in 
relation to drug use. However, while objective measures would have been desirable, research 
suggests a high degree of concordance between self-report and objective measures of recent 
drug use from saliva (Yacoubian & Wish, 2006) and of longer term use from hair (Scholey et 
al. 2011; Vignali, Stramesi, Vecchio, Groppi, 2012). Furthermore, concordance between self-
reports and objective measures of drug use has been demonstrated for multiple illicit drugs 
(Vignali et al. 2012), cannabis and cocaine (Vignali et al. 2012; Zaldívar et al. 2009) and 
ecstasy (Scholey et al. 2011; Yacoubian & Wish, 2006). Obviously it neither ethical nor 
feasible to administer MDMA to humans for prolonged periods so we have used an 
opportunity sample. Clearly we cannot exclude the possibility that our groups differed on 
some other pre-existing condition predating their drug use or in terms of some other lifestyle 
variable. While we have attempted to control for a number of potential confounds, there may 
be others perhaps as yet unknown which may have had an impact on the results reported here. 
In conclusion, the present study has identified clear long-term dose-related effects of 
ecstasy use on PM performance and in doing so has furthered the current understanding of 
the basis of PM deficits among ecstasy users. Outside the laboratory, the results obtained may 
also have utility in informing the development of harm reduction interventions by 
highlighting the potential risks associated with taking large number of tablets in a single 
session.  
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Table 1: Demographic Variables, Prospective Memory Outcomes and Drug Use Indicators: Study 1  
 Ecstasy/Polydrug Users Non-ecstasy Users p  
 Mean SD n Mean SD n  
Age 21.91 2.40 64 20.89 2.38 85 .012 
Ravens progressive matrices 
(maximum 60) 
43.95 7.80 62 45.26 8.13 82 ns 
Years of education 16.15 1.67 56 15.82 1.90 78 ns 
Alcohol (units per week) 13.85 10.47 62 12.49 11.85 75 ns 
Cigarettes per day 3.61 4.58 65 1.15 3.44 85 <.001 
        
Fatigue: Short-term 
time based PM (%) 
       
Total 54.33 28.39 65 71.40 25.30 82 <.001 
First Half 70.26 30.96 65 79.82 29.07 82 (.056) 
Second Half 38.87 34.27 65 62.99 35.21 82 <.001 
        
Mail:  Long-term time based 
PM   
0.89 1.23 65 1.39 1.35 84 .021 
        
F1: Event based PM         
Total 1.77 2.83 64 0.71 1.48 85 .004 
Trial 1  0.78 1.19 64 0.46 0.96 85 (.069) 
Trial 2 0.53 1.11 64 0.12 0.45 85 .002 
Trial 3 0.45 0.97 64 0.13 0.57 85 .012 
        
Total Prior Consumption        
Cannabis (joints) 1658.02 3162.11 52 485.65 1423.81 30 .024 
Cocaine (lines) 616.90 994.41 43 54.28 81.97 4  
Ecstasy (tablets) 316.51 654.56 60 - - -  
        
Current Frequency of Use 
(times per week) 
       
Cannabis 2.46 8.60 55 0.43 1.25 35 ns 
Cocaine 0.43 0.80 47 0.16 0.28 7  
Ecstasy 0.16 0.25 64 - - -  
        
Weeks since last usea        
Cannabis 31.05 56.87 57 78.47 106.37 37 .016 
Cocaine 31.61 58.93 49 31.14 40.40 9  
Ecstasy 52.43 72.72 65 - - -  
        
 
a. The median period of abstinence from cannabis was 8 and 16 weeks for ecstasy/polydrug 
users and non-ecstasy users respectively. The equivalent figures for cocaine were 8 and 20 
weeks. The median period of abstinence for ecstasy was 12 weeks. 
 Table 2: Demographic Variables, Current Consumption of Alcohol and Cigarettes and Prospective Memory Outcomes: Study 2 
 Ecstasy/Polydrug Users Cannabis only users Nonusers p value (two-tailed) for oneway 
ANOVA and Tukey’s HSD 
    Overall E/P vs 
Non 
Cannvs 
Non 
E/P 
vsCann 
 Mean SD n Mean SD n Mean SD n     
Age 21.85 2.98 102 21.47 3.00 38 20.64 2.23 65  .024 .018   
Ravens progressive matrices 
(maximum 60) 
44.00 8.99 99 45.71 7.04 38 44.78 8.31 63  ns    
Years of education 15.25 3.20 93 15.55 2.32 33 15.30 2.22 63  ns    
Alcohol (units per week) 14.44 10.32 99 13.66 11.48 35 8.19 10.20 59  .001 .001 .041  
Cigarettes per day 4.17 6.16 103 1.53 3.17 38 0.98 3.63 65 <.001 <.001  .016 
              
Fatigue: Short-term 
time based PM (%) 
             
Total 47.37 28.47 103 61.07 23.44 36 77.15 22.05 64 <.001 <.001 .009 .018 
First Half 63.41 34.15 103 72.13 30.88 36 84.63 22.88 64 <.001 <.001   
Second Half 28.40 32.08 103 44.31 37.80 36 69.80 32.40 64 <.001 <.001 .001 .038 
              
Mail:  Long-term time based 
PM   
0.86 1.21 103 1.18 1.23 38 1.58 1.32 64 .002 .001   
              
F1: Event based PM               
Total 1.75 2.74 102 0.74 1.11 38 0.60 1.48 65 .001 .003  .037 
Trial 1  0.82 1.20 102 0.61 1.00 38 0.38 0.91 65 .038 .030   
Trial 2 0.50 1.09 102 0.05 0.23 38 0.08 0.41 65 .001 .003  .011 
Trial 3 0.43 0.96 102 0.08 0.27 38 0.14 0.63 65 .015 .048  .046 
              
 
 Table 3: Measures of Illicit Drug Use for Ecstasy/Polydrug and Cannabis-Only Users: Study 2 
 
  Ecstasy/Polydrug User Cannabis Only User p 
 Median Mean SD n Median Mean SD n  
Long-Term Average Dose 
Per Session 
         
Cannabis (joints) 2.20 2.71 1.89 85 1.00 1.36 0.88 31 <.001 
Cocaine (lines) 4.83 6.49 6.53 64 - - - -  
Ecstasy (tablets) 2.00 2.95 3.80 97 - - - -  
Long-Term Average 
Frequency (times per 
week) 
         
Cannabis 1.00 1.74 2.07 85 0.23 1.02 1.69 31 .084 
Cocaine 0.23 0.52 0.66 64 - - - -  
Ecstasy 0.23 0.54 0.91 97 - - - -  
          
          
Total Prior Consumption          
Cannabis (joints) 442.00 2110.56 3646.62 85 23.92 473.10 1404.83 31 .001 
Cocaine (lines) 247.52 695.78 1113.89 64 - - - -  
Ecstasy (tablets) 63.44 420.28 887.38 97 - - - -  
Average weekly 
consumption 
         
Cannabis (joints) 2.04 7.98 11.69 87 0.68 2.47 4.71 30 <.001 
Cocaine (lines) 2.17 28.99 164.11 63 - - - -  
Ecstasy (tablets) 1.16 2.55 3.67 95 - - - -  
Duration of use (weeks)          
Cannabis 264.00 297.06 192.80 91 108.00 180.35 199.27 37 .003 
Cocaine 127.57 159.96 124.93 75 - - - -  
Ecstasy 133.50 160.48 139.92 102 - - - -  
          
Current Frequency of Use 
(times per week) 
         
Cannabis 0.24 1.86 6.81 90 0.01 0.53 1.45 36 .249 
Cocaine 0.14 0.43 0.72 70 - - - -  
Ecstasy  0.04 0.17 0.26 102 - - - -  
Weeks since last use          
Cannabis 4.00 32.07 63.72 92 24.00 77.35 92.57 37 .009 
Cocaine 8.00 29.86 59.21 77 - - - -  
Ecstasy 12.00 45.93 70.59 103 - - - -  
          
  
Table 4: Association between Long Term Average Dose and Frequency of Use of Major Illicit Drugs 
and Prospective Memory Outcomes 
 
*p<.10; **p<.05; *** p< .01121 and FWE <.05 ; †FDR<.10 with m=48; all two tailed 
 n Zero-Order Correlation with:   
Fatigue: Short-term  
Time-based PM 
Mail:  Long- 
term time- 
based PM  
F1: Event-based PM 
  Total First Half Second 
Half 
 Total Trial 1 Trial 2 Trial 3 
Long-Term Average Dose 
Per Session 
         
Cannabis (joints) 123 -.141 -.131 -.121 -.066 .120 .074 .139 .086 
Cocaine (lines) 70 -.260** -.195 -.229* .092 .006 .225* -.115 -.112 
Ecstasy (tablets) 96 -.300***† -.320***† -.183* -.158 .295***† .249**† .232** .268***† 
Long-Term Average 
Frequency (times per 
week) 
         
Cannabis 123 -.246***† -.256***† -.141 -.151* .109 .071 .115 .085 
Cocaine 70 -.089 -.141 -.074 .029 .163 .149 .148 .119 
Ecstasy 96 -.117 -.140 -.034 -.008 .096 .139 .054 .039 
 
          
          
 Table 5: Association between More Commonly Used Measures of Illicit Drug Use and Prospective 
Memory Outcomes 
 
*p<.10; **p<.05; *** p< .00879 and FWE<.05; †FDR<.10 with m=120; all two tailed;  
(*) indicates that although p<.10, the effect was not in the predicted direction 
 
 
 
 n Zero-Order Correlation with:   
Fatigue: Short-term  
Time-based PM 
Mail:  Long- 
term time- 
based PM  
F1: Event-based PM 
  Total First Half Second 
Half 
 Total Trial 1 Trial 2 Trial 3 
 
Total Prior Consumption 
         
Cannabis (joints) 123 -.128 -.104 -.126 -.079 .038 .008 .041 .051 
Cocaine (lines) 70 -.072 -.045 -.129 .120 .083 .330*** -.073 -.066 
Ecstasy (tablets) 96 -.182 -.213** -.075 -.090 .206 .189* .166 .166 
Average weekly 
consumption 
         
Cannabis (joints) 125 -.191 -.171* -.123 -.160* .032 .000 .069 .012 
Cocaine (lines) 69 -.063 -.092 .005 -.076 -.087 -.082 -.069 -.071 
Ecstasy (tablets) 94 -.234 -.278*** -.101 -.065 .195 .176* .151 .172* 
Duration of use (weeks)          
Cannabis 136 -.097 -.036 -.145* -.029 .069 .040 .087 .043 
Cocaine 85 -.062 -.073 -.105 -.059 .161 .232** .152 .014 
Ecstasy 101 -.014 -.015 -.018 -.006 .019 .026 .050 -.036 
          
Current Frequency of Use 
(times per week) 
         
Cannabis 133 .125 .064 .154(*) .105 .046 -.033 .047 .128 
Cocaine 78 .081 -.012 .144 -.067 .033 .196* -.061 -.071 
Ecstasy 101 -.192 -.170* -.152 -.049 .149 .065 .182* .139 
Weeks since last use          
Cannabis 137 .155 .128 .084 -.058 -.184 -.137 -.170** -.142* 
Cocaine 88 .150 .225** .073 .024 -.131 -.092 -.116 -.132 
Ecstasy 102 .120 .130 .076 -.178(*) .093 .151 .030 .042 
          
